Rivus Pharmaceuticals is a biotechnology company focused on developing innovative therapies for the treatment of rare and infectious diseases.

Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). For more information please visit https://www.rivuspharma.com/

RxCapital

Longitude Capital

Medicxi

Bain Capital Life Sciences

BB Biotech Ventures

RA Capital Management

Rivus Pharmaceuticals 

We're developing a new class of investigational medicines that target energy consumption instead of energy intake, resulting in fat-specific weight-loss. Our CEO, Dr. Jayson Dallas, shares with PharmaVoice how our unique therapeutic approach stands out amidst a crowded landscape and how we are aiming to go beyond obesity to treat cardiometabolic diseases. Read more: https://bit.ly/3IUnp1T 

COM:RIVUSPHARMA

Rivus Pharmaceuticals

Analysis Not Available